When managing severe, treatment-refractory Hidradenitis Suppurativa exhibiting incomplete response to single biologic agents, what safety parameters, diagnostic biomarkers, and/or monitoring protocols govern your decision to utilize off-label dual targeted therapy (e.g., combining a JAK inhibitor with an IL-17 or TNF inhibitor)?